Hubert Max Ole, Mayerle Julia, Sirtl Simon
Medizinische Klinik und Poliklinik II, LMU Klinikum München, Marchioninistr. 15, 81377, München, Deutschland.
Inn Med (Heidelb). 2025 May;66(5):524-532. doi: 10.1007/s00108-025-01888-3. Epub 2025 Apr 29.
Drugs are a rare but important cause of acute pancreatitis (AP) due to potential therapeutic consequences, accounting for up to 5% of all cases of AP. The diagnosis of drug-induced AP is challenging due to mostly weak evidence and complex diagnostic criteria.
This review article defines drug-induced AP, summarizes the evidence for drugs associated with AP and highlights the challenges in the diagnosis of this condition. The second part of the article focuses on the main pillars of AP treatment.
The association of most drugs associated with AP is based on case reports and case series but there are no high-quality studies. There is sufficient evidence of a causal relationship for only 40 of more than 500 drugs associated with AP and for almost none of the drugs the causal mechanism has been definitively clarified. Several classification systems and criteria have been proposed to assess whether a drug causally triggers AP, with criteria including the temporal association, the exclusion of other causes and recurrence of AP after re-exposure.
The diagnosis of drug-induced AP remains a challenge, with many common drugs being incorrectly associated with AP. There is an urgent need for the development of biomarkers to facilitate the diagnosis of drug-induced AP. Drug treatment for AP is still primarily a needs-based fluid management and efficient analgesia. New and causal therapeutic approaches need clinical validation.
由于潜在的治疗后果,药物是急性胰腺炎(AP)的一种罕见但重要的病因,占所有AP病例的5%。药物性AP的诊断具有挑战性,因为证据大多薄弱且诊断标准复杂。
这篇综述文章对药物性AP进行了定义,总结了与AP相关药物的证据,并强调了这种疾病诊断中的挑战。文章的第二部分重点关注AP治疗的主要支柱。
大多数与AP相关的药物关联是基于病例报告和病例系列,但缺乏高质量研究。在500多种与AP相关的药物中,只有40种有充分证据证明存在因果关系,而且几乎没有一种药物的因果机制得到明确阐明。已经提出了几种分类系统和标准来评估一种药物是否因果性引发AP,标准包括时间关联、排除其他病因以及再次接触后AP复发。
药物性AP的诊断仍然是一个挑战,许多常用药物被错误地认为与AP有关。迫切需要开发生物标志物以促进药物性AP的诊断。AP的药物治疗仍然主要是基于需求的液体管理和有效的镇痛。新的因果治疗方法需要临床验证。